Here, the authors show that TRAF3 is upregulated in the liver in non-alcoholic fatty liver disease, promoting insulin resistance, inflammation and hepatic steatosis via its interaction with the kinase TAK1. Here, TRAF3 is linked to metabolic dysfunction-associated steatotic liver disease.